Patents by Inventor William Hagopian

William Hagopian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for screening for genetic predisposition to type I diabetes
    Patent number: 8268561
    Abstract: A method of genetically screening large numbers of individuals to identify those individuals requiring follow-up testing for active Type I diabetes (T1D) is provided. The method includes obtaining a nucleic-acid containing biological sample from each individual and testing for the presence of specific combinations of HLA II alleles in the sample.
    Type: Grant
    Filed: April 8, 2009
    Date of Patent: September 18, 2012
    Assignee: Pacific Northwest Research Institute
    Inventors: William Hagopian, Hui Peng
  • METHODS FOR SCREENING FOR GENETIC PREDISPOSITION TO TYPE I DIABETES
    Publication number: 20090311697
    Abstract: A method of genetically screening large numbers of individuals to identify those individuals requiring follow-up testing for active Type I diabetes (T1D) is provided. The method includes obtaining a nucleic-acid containing biological sample from each individual and testing for the presence of specific combinations of HLA II alleles in the sample.
    Type: Application
    Filed: April 8, 2009
    Publication date: December 17, 2009
    Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTE
    Inventors: William HAGOPIAN, Hui PENG
  • Islet cell antigen 1851
    Patent number: 6627735
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: September 30, 2003
    Assignee: ZymoGenetics, Inc.
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Islet cell antigen 1851
    Publication number: 20030166067
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Application
    Filed: April 16, 2002
    Publication date: September 4, 2003
    Applicant: ZymoGenetics, Inc.
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Islet cell antigen 1851
    Publication number: 20020102616
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Application
    Filed: June 7, 2001
    Publication date: August 1, 2002
    Applicant: ZymoGenetics, Inc.
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Islet cell antigen 1851
    Patent number: 6300093
    Abstract: A mammalian islet cell antigen polypeptide involved in the development of insulin-dependent diabetes mellitus (IDDM) is disclosed. This islet cell antigen polypeptide, 1851, was found to contain regions of homology to the protein tyrosine phosphatase family. Methods for diagnosis and treatment, including use in immunoprecipitation assays and the induction of immune tolerance using the recombinant mammalian polypeptides and antibodies specific to mammalian islet cell antigen 1851 polypeptides are presented.
    Type: Grant
    Filed: March 5, 1997
    Date of Patent: October 9, 2001
    Assignees: ZymoGenetics, Inc., University of Washington
    Inventors: Wayne Kindsvogel, Laura J. Jelinek, Paul O. Sheppard, William A. Hagopian, James M. LaGasse
  • Cloning and expression of human islet glutamic acid decarboxylase autoantigen
    Patent number: 6025176
    Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: February 15, 2000
    Assignee: The Board of Regents of the University of Washington and ZymoGenetics, Inc.
    Inventors: Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
  • Cloning and expression of human islet glutamic acid decarboxylase autoantigen
    Patent number: 5792620
    Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.
    Type: Grant
    Filed: August 17, 1993
    Date of Patent: August 11, 1998
    Assignees: The Board of Regents of the University of Washington, ZymoGenetics, Inc.
    Inventors: Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
  • Diagnosis of insulin-dependent diabetes
    Patent number: 5547847
    Abstract: Methods for predicting the clinical course of diabetes in patients diagnosed as having NIDDM are provided. Patients having NIDDM are tested for the presence of autoantibodies to human islet cell glutamic acid decarboxylase. Based on the presence or absence of autoantibodies, the patients are classified as to the predicted course of the disease. These methods can be used to predict the development of IDDM and to guide therapeutic intervention.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: August 20, 1996
    Assignee: University of Washington
    Inventors: William Hagopian, Ake Lernmark, Allan E. Karlsen, Mona Landin-Olsson